Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure (MICRORAH)
29 april 2016 uppdaterad av: Daniel Alexandre Bottino
Inflammatory Biomarkers and Endothelial Function Assessed by Venous Occlusion Plethysmography and Nailfold Videocapillaroscopy in Patients With Resistant Hypertension, Stages 1 and 2 and Normotensive
Nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and inflammatory biomarkers have been used to study endothelial function in patients with resistant hypertension, stages 1 and 2 hypertension and normotensive.
This was a cross-sectional study.
Studieöversikt
Status
Avslutad
Betingelser
Detaljerad beskrivning
Microcirculation determines peripheral resistance contributing to increased blood pressure.
The nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and biomarkers can be used to evaluate the microcirculation in arterial hypertension (AH).
The objective of this study is to analyze the behavior of serum inflammatory markers and study the microcirculation by nailfold videocapillaroscopy (NVC) and Venous Occlusion Plethysmography in patients with resistant hypertension (RH), with stages 1 and 2 hypertension (MMH ) and normotensive (CG).
A cross-sectional study with 75 patients has been performed: 25 with resistant hypertension (RH), 25 with stages 1 and 2 hypertension (MMH) and 25 normotensive (CG).
All underwent anamnesis, dosage serum markers and conducting NVC, VOP.
Hypertensive patients without statin use and with controlled or uncontrolled blood pressure were also analyzed.
For the statistical analysis were used: Kruskal -Wallis ANOVA, Dunn test and ANCOVA for correction of confusion factors such as age and BMI.
Studietyp
Observationell
Inskrivning (Faktisk)
75
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
27 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
First Day: Full clinical examination was performed, including measurements of at-rest blood pressure, weight and height in order to calculate Body Mass Index (BMI), waist and hip measurements.
Second Day: drawing blood for laboratory analyses, Nailfold Videocapillaroscopy and Venous Occlusion Plethysmography.
Beskrivning
Inclusion Criteria:
- Clinical diagnosis of controlled High Blood Pressure stages 1 and 2 (blood pressure levels from 140/90 mmHg to 179/109 mmHg) .
- Resistant Hypertension (uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs).
- Normal Blood Pressure.
Exclusion Criteria:
- Diabetes Mellitus, Types 1 or 2.
- Heart Failure.
- Myocardial infarction or stroke with less than three months of the event.
- Chronic kidney disease.
- Use of hormonal or non-hormonal anti-inflammatory drugs.
- Recent trauma (less than three months).
- Autoimmune diseases.
- Infectious processes in activity.
- Neoplasia.
- Aspirin use (anti-inflammatory dose).
- Obesity grade III (Body Mass Index>40 kg/m2).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Resistant Hypertension (RH)
uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
|
|
Stages 1 and 2 Hypertension (MMH)
According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
|
|
Normotensive (CG)
Blood Pressure <140/90 mmHg and without comorbidities.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Blood Pressure (mmHg)
Tidsram: 1 day
|
Hemodynamic Variable
|
1 day
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Functional Capillary Density (FCD, number capillaries/mm2 )
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Afferent Capillary Diameter (micrometer)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Apical Capillary Diameter (micrometer)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Efferent Capillary Diameter (micrometer)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Red Blood Cell Velocity (mm/s)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Maximum Red Blood Cell Velocity (mm/s)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Time to reach Maximum Red Blood Cell Velocity (s)
Tidsram: 1 day
|
Microcirculatory variable from Nailfold Videocapillaroscopy
|
1 day
|
|
Waist circumference (cm)
Tidsram: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Hip circumference (cm)
Tidsram: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Waist to Hip Ratio
Tidsram: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Body Mass Index (Kg/m2)
Tidsram: 1 day
|
Anthropometrical Variable
|
1 day
|
|
Maximal Forearm Blood Flow during reactive Hyperemia
Tidsram: 1 day
|
Vascular Reactivity Variables from Venous Occlusion Plethysmography
|
1 day
|
|
Maximal Forearm Blood Flow after sublingual nitroglycerine
Tidsram: 1 day
|
Vascular Reactivity Variables from Venous Occlusion Plethysmography
|
1 day
|
|
Vascular Cell Adhesion Molecule (VCAM, ng/dl)
Tidsram: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Intercellular Adhesion Molecule (ICAM, ng/dl)
Tidsram: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Adiponectin (ng/dl)
Tidsram: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
Endothelin (pg/dl)
Tidsram: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
|
C Reactive Protein (CRP, mg/dl)
Tidsram: up to 2 weeks
|
Inflammatory Biomarker
|
up to 2 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 maj 2015
Primärt slutförande (Faktisk)
1 december 2015
Avslutad studie (Faktisk)
1 december 2015
Studieregistreringsdatum
Först inskickad
20 april 2016
Först inskickad som uppfyllde QC-kriterierna
29 april 2016
Första postat (Uppskatta)
3 maj 2016
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
3 maj 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 april 2016
Senast verifierad
1 april 2016
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RiodeJaneiro_StateUniversity
- BIOVASC-UERJ (Annan identifierare: Clinical and Experimental Research Lab on Vascular Biology)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .